Allston, MA – According to filings with the U.S. Securities and Exchange Commission, Concerto Biosciences is raising $24,541,949.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Cheri Ackerman played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Concerto Biosciences
Concerto Biosciences reinvents humanitys relationship with microbes. We envision a future where each of us fine-tunes the microbial communities in us, on us, and around us to stay healthy. To pave the way, Concerto invented a platform to measure, in ultra-high throughput, how microbes behave in the presence of each other. These measurements enable Concerto to see the world as it is: a massive underlying network of microbial interactions that shapes the health of our bodies and our planet. The network reveals new products ensembles of microbes that work in concert to perform tasks that benefit people. Our first ensembles rehabilitate the skin microbiome, providing protection from previously intractable diseases like eczema and restoring health to millions.

To learn more about Concerto Biosciences, visit http://www.concertobio.com/

Contact:
Cheri Ackerman, Chief Executive Officer
617-544-7044
cheri@concertobio.com
https://www.linkedin.com/in/cheriackerman/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved